Loading stock data…
$29.23+0.18 (+0.62%)
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
Lakefront Biotherapeutics NV in the Healthcare sector is trading at $29.29 with a market capitalization of $1.8B. Wall Street consensus targets $29.99 (3 analysts), implying a +2.4% move over the next 12 months. The stock is currently 19% below its 52-week high of $36.24, remaining 2.5% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $12.11M↑ | $6.48M↓ | $900.82M↑ | $71.16M↑ | $65.29M |
| Gross Profit | $2.96M↑ | $1.68M↓ | $900.37M↑ | $60.31M↓ | $60.58M |
| Operating Income | -$43.51M↑ | -$63.70M↓ | $758.80M↑ | -$41.67M↑ | -$57.03M |
| Net Income | $2.11M↓ | $14.49M↓ | $782.15M↑ | -$202.11M↓ | -$105.75M |
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermat...